financetom
OPRX
financetom
/
Healthcare
/
OPRX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
OptimizeRx CorporationOPRX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
145.15M
Revenue (ttm)
92.13M
Net Income (ttm)
-20.11M
Shares Out
18.49M
EPS (ttm)
-1.10
PE Ratio
n/a
Forward PE
20.62
Dividend
n/a
Ex-Dividend Date
n/a
Volume
61,326
Open
8.25
Previous Close
8.16
Day's Range
7.76 - 8.24
52-Week Range
3.78 - 14.13
Beta
1.18
Analysts
Buy
Price Target
9.06 (+15.41%)
Earnings Date
May 13, 2025
Description >

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients.

Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.

The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems.

In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs.

The company was founded in 2006 and is headquartered in Rochester, Michigan.

Latest News >
Xali Gold Says Remedioambiente to Start Underground Work at El Oro Project in Mexico
Xali Gold Says Remedioambiente to Start Underground Work at El Oro Project in Mexico
Jan 29, 2025
08:21 AM EST, 01/29/2025 (MT Newswires) -- Xali Gold ( CGDXF ) said Wednesday that it reached a definitive agreement allowing Remedioambiente to start underground test work at the El Oro project in Mexico. Xali said initial work will focus on identifying the most effective recovery methods for gold and silver, as well as establishing the best underground access. The...
Avnet Fiscal Q2 Adjusted Earnings, Revenue Decline; Fiscal Q3 Outlook Issued
Avnet Fiscal Q2 Adjusted Earnings, Revenue Decline; Fiscal Q3 Outlook Issued
Jan 29, 2025
08:25 AM EST, 01/29/2025 (MT Newswires) -- Avnet (AVT) reported fiscal Q2 adjusted earnings Wednesday of $0.87 per diluted share, down from $1.40 a year earlier. Analysts polled by FactSet expected $0.89. Sales for the quarter ended Dec. 28 were $5.66 billion, down from $6.2 billion a year earlier. Analysts surveyed by FactSet expected $5.58 billion. For fiscal Q3, the...
LyondellBasell signs renewable power purchase agreements in Europe
LyondellBasell signs renewable power purchase agreements in Europe
Jan 29, 2025
(Reuters) - Petrochemicals manufacturer LyondellBasell said on Wednesday it has signed power purchase agreements in Europe for wind energy to support its commitment to reducing greenhouse gas emissions. Chemical companies are entering deals to purchase renewable electricity to help them reach their carbon dioxide emissions reduction targets. Under the 15-year agreement with European energy firm Vattenfall, LyondellBasell will secure 450...
Schlumberger's Proposed Acquisition of ChampionX Faces Inquiry by UK Regulator
Schlumberger's Proposed Acquisition of ChampionX Faces Inquiry by UK Regulator
Jan 29, 2025
08:28 AM EST, 01/29/2025 (MT Newswires) -- Schlumberger ( SLB ) and ChampionX's ( CHX ) proposed merger will be placed under a phase 1 inquiry by the UK Competition and Markets Authority, according to a Wednesday statement by the regulator. The CMA said the inquiry period will begin Thursday and it targets to issue a decision by March 27...
Copyright 2023-2025 - www.financetom.com All Rights Reserved